Pterostilbene

Pterostilbene is a stilbenoid polyphenol found in blueberries, grapes, and the heartwood of the Pterocarpus marsupium tree. It is structurally similar to resveratrol but differs by having two methoxy groups instead of hydroxyl groups, which significantly improves its oral bioavailability and metabolic stability. This makes pterostilbene an attractive candidate for oral delivery formats like gummies and sachets, where absorption efficiency is a key formulation consideration.

Brands use pterostilbene to position products in the healthy ageing, cognitive wellness, and antioxidant protection segments. It is often described as a "next-generation" polyphenol because of its superior pharmacokinetic profile compared to resveratrol. In the EU market, pterostilbene is not a novel food ingredient and has a history of consumption as a dietary constituent, but it carries no EFSA-authorised health claims. Claim strategy must therefore rely on co-formulated nutrients or general wellness positioning.

Origin and history

Pterostilbene was first identified in the 1970s as a constituent of the heartwood of Pterocarpus marsupium, a tree native to India and Southeast Asia traditionally used in Ayurvedic medicine. It was later found in blueberries (Vaccinium spp.) and grapes (Vitis vinifera), where it acts as a phytoalexin — a compound produced by the plant in response to stress or infection. The compound's name derives from the plant genus Pterocarpus and the stilbene backbone common to this chemical family.

Industrial production of pterostilbene today is primarily through chemical synthesis, which yields high-purity material at a lower cost than extraction from natural sources. Naturally-derived pterostilbene is also available, typically extracted from blueberry or Pterocarpus marsupium sources, but commands a premium price. The ingredient gained commercial traction in the dietary supplement market in the 2010s as research into its bioavailability and biological activity expanded, positioning it as a premium alternative to resveratrol.

Scientific overview

Pterostilbene's mechanism of action is similar to resveratrol but with key differences in bioavailability and metabolism. The two methoxy groups on pterostilbene's structure make it more lipophilic and resistant to glucuronidation and sulfation in the liver and intestine, resulting in significantly higher oral bioavailability. Studies indicate that pterostilbene achieves approximately 80% oral bioavailability in animal models, compared to around 20% for resveratrol. This means lower doses can achieve comparable systemic exposure, which is advantageous for gummy formulations where dose volume is limited.

The compound is known to activate the sirtuin pathway (particularly SIRT1) and AMPK, both involved in cellular energy regulation and stress resistance. It also exhibits antioxidant activity through direct free radical scavenging and upregulation of endogenous antioxidant enzymes via the Nrf2 pathway. These mechanisms underpin its positioning in healthy ageing and cognitive wellness products. Pterostilbene also modulates inflammatory signalling pathways, though this mechanism cannot be used as a claim in EU consumer-facing copy.

From a manufacturing perspective, pterostilbene is heat-stable and has a mild taste profile, making it suitable for gummy production. However, its lipophilic nature requires careful dispersion in the gummy matrix to ensure homogeneity. Microencapsulated or solubilised forms are available and can improve dispersion and stability. The ingredient is typically used at 50–250 mg per serving, with 50–100 mg being common for maintenance positioning and higher doses for targeted wellness applications. Cost-per-mg is higher than resveratrol, reflecting its premium positioning and more complex synthesis.

Pterostilbene occupies a premium position in the healthy ageing and cognitive wellness market, often alongside NAD+ precursors and other longevity ingredients. It is one of the most familiar and commercially understood premium actives in this space across EU and US markets. Brands use it to differentiate their product lines from standard antioxidant offerings, targeting consumers who are knowledgeable about bioavailability and ingredient quality. The ingredient's association with blueberries provides a natural, clean-label story that resonates with health-conscious consumers.

From a formulation perspective, pterostilbene is well-suited to gummy manufacturing. Its heat stability allows it to withstand the cooking and drying stages of gummy production without significant degradation. The mild taste profile means it does not require aggressive masking, and it can be incorporated into fruit-flavoured gummy bases with minimal impact on sensory properties. The main formulation challenge is ensuring even dispersion of this lipophilic compound throughout the gummy matrix. DAT reviews dispersion strategies per project, including the use of emulsifiers or microencapsulated forms. The premium cost of pterostilbene means it is typically used in higher-margin product lines.

For pack copy, brands must exercise strict claim discipline in the EU market. Pterostilbene has no EFSA-authorised health claims, so all consumer-facing claims must be based on co-formulated nutrients with authorised claims under Reg. 432/2012. For example, a gummy containing pterostilbene and Vitamin C can carry the authorised claim "Vitamin C contributes to the protection of cells from oxidative stress." Pterostilbene itself can be described factually as a "naturally occurring polyphenol found in blueberries" without making specific health claims. DAT reviews claim strategy per project and confirms certification status (vegan, kosher, halal) per batch documentation. Shelf-life claims are confirmed per project with stability data.